Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France

Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .

The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

HIV - Human Immunodeficiency Virus Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Migrants RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Socio-economic Status Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Clermont-Ferrand University Hospital

Clermont-Ferrand, France, 63000

Location contact

Aida ZAGHDOUDI, Medical Doctor

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults (≥18 years of age);
Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.

Non-inclusion Criteria:

Patients who declined to participate in the study;
Patients who do not speak French and for whom no interpretere was available
Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)

Treatment and study plan

Primary outcomes

HIV immuno-virological status

Time frame: Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029

To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Laclautre

CONTACT

[email protected]

+33473754963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: PrimoAVIH

Important dates

Study start: 2026
Primary completion: 2029
Study completion: 2030
First posted: Jul 8, 2026
Registry last updated: Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting